Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties INDIANAPOLIS and TEL AVIV , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd.